None of 32 UK bowel cancer patients saw their disease return after 33 months on pembrolizumab
The NEOPRISM-CRC trial gave immunotherapy before surgery instead of the usual post-operative chemotherapy. In 59% of participants, no detectable disease remained after treatment — and none of the 32 had a recurrence at the 33-month mark.
2 min read